425 related articles for article (PubMed ID: 31586665)
1. Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms.
Kang J; Ning MS; Feng H; Li H; Bahig H; Brooks ED; Welsh JW; Ye R; Miao H; Chang JY
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):90-99. PubMed ID: 31586665
[TBL] [Abstract][Full Text] [Related]
2. Predicting Overall Survival After Stereotactic Ablative Radiation Therapy in Early-Stage Lung Cancer: Development and External Validation of the Amsterdam Prognostic Model.
Louie AV; Haasbeek CJ; Mokhles S; Rodrigues GB; Stephans KL; Lagerwaard FJ; Palma DA; Videtic GM; Warner A; Takkenberg JJ; Reddy CA; Maat AP; Woody NM; Slotman BJ; Senan S
Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):82-90. PubMed ID: 26138912
[TBL] [Abstract][Full Text] [Related]
3. Nomograms for predicting disease progression in patients of Stage I non-small cell lung cancer treated with stereotactic body radiotherapy.
Ye L; Shi S; Zeng Z; Huang Y; Hu Y; He J
Jpn J Clin Oncol; 2018 Feb; 48(2):160-166. PubMed ID: 29253245
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Stahl JM; Ross R; Harder EM; Mancini BR; Soulos PR; Finkelstein SE; Shafman TD; Dosoretz AP; Evans SB; Husain ZA; Yu JB; Gross CP; Decker RH
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1011-1020. PubMed ID: 27869080
[TBL] [Abstract][Full Text] [Related]
5. Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy.
Zhao L; Zhou S; Balter P; Shen C; Gomez DR; Welsh JD; Lin SH; Chang JY
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1226-35. PubMed ID: 27209498
[TBL] [Abstract][Full Text] [Related]
6. Nomogram Predicting Overall Survival Benefit of Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
Jacobs CD; Mehta K; Gao J; Wang X; Salama JK; Kelsey CR; Torok JA
Clin Lung Cancer; 2022 Mar; 23(2):177-184. PubMed ID: 34301453
[TBL] [Abstract][Full Text] [Related]
7. Response criteria in solid tumors (PERCIST/RECIST) and SUV
Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
[TBL] [Abstract][Full Text] [Related]
8. Development and external validation of a nomogram to predict overall survival following stereotactic body radiotherapy for early-stage lung cancer.
Baker S; Bakunina K; Duijm M; Hoogeman MS; Cornelissen R; Antonisse I; Praag J; Heemsbergen WD; Nuyttens JJ
Radiat Oncol; 2020 Apr; 15(1):89. PubMed ID: 32321553
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic Ablative Radiation Therapy for Pulmonary Recurrence-Based Oligometastatic Non-Small Cell Lung Cancer: Survival and Prognostic Value of Regulatory T Cells.
Liu C; Sun B; Hu X; Zhang Y; Wang Q; Yue J; Yu J
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1055-1064. PubMed ID: 31437470
[TBL] [Abstract][Full Text] [Related]
10. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
Dang J; Xu G; Guo G; Zhang H; Shang L
J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
[TBL] [Abstract][Full Text] [Related]
11. Impact of pretreatment tumor growth rate on outcome of early-stage lung cancer treated with stereotactic body radiation therapy.
Atallah S; Cho BC; Allibhai Z; Taremi M; Giuliani M; Le LW; Brade A; Sun A; Bezjak A; Hope AJ
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):532-8. PubMed ID: 24929163
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer.
Brooks ED; Sun B; Zhao L; Komaki R; Liao Z; Jeter M; Welsh JW; O'Reilly MS; Gomez DR; Hahn SM; Heymach JV; Rice DC; Chang JY
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):900-907. PubMed ID: 28258887
[TBL] [Abstract][Full Text] [Related]
13. The development and external validation of an overall survival nomogram in medically inoperable centrally located early-stage non-small cell lung carcinoma.
Duijm M; Oomen-de Hoop E; van Voort van der Zyp N; van de Vaart P; Tekatli H; Hoogeman M; Senan S; Nuyttens J
Radiother Oncol; 2021 Mar; 156():223-230. PubMed ID: 33418006
[TBL] [Abstract][Full Text] [Related]
14. Five-year Long-term Outcomes of Stereotactic Body Radiation Therapy for Operable Versus Medically Inoperable Stage I Non-small-cell Lung Cancer: Analysis by Operability, Fractionation Regimen, Tumor Size, and Tumor Location.
Schonewolf CA; Heskel M; Doucette A; Singhal S; Frick MA; Xanthopoulos EP; Corradetti MN; Friedberg JS; Pechet TT; Christodouleas JP; Levin W; Berman A; Cengel KA; Verma V; Hahn SM; Kucharczuk JC; Rengan R; Simone CB
Clin Lung Cancer; 2019 Jan; 20(1):e63-e71. PubMed ID: 30337269
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic ablative radiotherapy as single treatment for early stage non-small cell lung cancer: A single institution analysis.
Zheng X; Sun Y; Ye K; Fan C; Wang X; Yang Y; Jiao R; Ge H
Thorac Cancer; 2021 Mar; 12(6):899-905. PubMed ID: 33529496
[TBL] [Abstract][Full Text] [Related]
16. A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): Results of a propensity score-matched analysis.
Chiang A; Thibault I; Warner A; Rodrigues G; Palma D; Soliman H; Jain S; Poon I; Cheung P
Radiother Oncol; 2016 Mar; 118(3):478-84. PubMed ID: 26795773
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer: Comparing survival outcomes in adenocarcinoma and squamous cell carcinoma.
Abel S; Hasan S; White R; Schumacher L; Finley G; Colonias A; Wegner RE
Lung Cancer; 2019 Feb; 128():127-133. PubMed ID: 30642444
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic Ablative Radiotherapy for stage I histologically proven non-small cell lung cancer: an Italian multicenter observational study.
Ricardi U; Frezza G; Filippi AR; Badellino S; Levis M; Navarria P; Salvi F; Marcenaro M; Trovò M; Guarneri A; Corvò R; Scorsetti M
Lung Cancer; 2014 Jun; 84(3):248-53. PubMed ID: 24681279
[TBL] [Abstract][Full Text] [Related]
19. Predictors of Nodal and Metastatic Failure in Early Stage Non-small-cell Lung Cancer After Stereotactic Body Radiation Therapy.
Cerra-Franco A; Liu S; Azar M; Shiue K; Freije S; Hinton J; Deig CR; Edwards D; Estabrook NC; Ellsworth SG; Huang K; Diab K; Langer MP; Zellars R; Kong FM; Wan J; Lautenschlaeger T
Clin Lung Cancer; 2019 May; 20(3):186-193.e3. PubMed ID: 30711394
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
Lagerwaard FJ; Verstegen NE; Haasbeek CJ; Slotman BJ; Paul MA; Smit EF; Senan S
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):348-53. PubMed ID: 22104360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
